Ibogaine Draws New Interest as Detox Research Advances

Ibogaine, a psychedelic compound that some people have used to ease opioid withdrawal, is drawing fresh scientific and financial attention.

A Brazilian researcher says he has found a sustainable new plant source for the drug, and two U.S. states have committed millions of dollars to study it.

For anyone researching detox, the developments are a reminder that a compound with real promise can also carry serious, even fatal, medical risks that make professional supervision non-negotiable.

A Sustainable Source and New Funding

Ibogaine is traditionally extracted from the iboga shrub (Tabernanthe iboga), a plant native to Central Africa and considered sacred in the Bwiti tradition of Gabon.

Rising demand has put the wild plant under severe ecological pressure. The shrub can take up to 30 years to mature and yields only about a gram of ibogaine, and traditional harvesting often destroys the plant.

Ricardo Marques, a natural products chemist at the Federal University of Ceara, told Mongabay he has identified an Amazonian species that contains voacangine, a chemical precursor that can be converted into ibogaine.

He has declined to name the plant to prevent the kind of overharvesting seen in Africa, and says he developed a method that lets the plant regenerate after collection.

Funding is following the science. Last year, Texas and Arizona approved investments totaling $55 million to fund Food and Drug Administration approved clinical trials of ibogaine.

Understanding Ibogaine and Its Risks

Interest in ibogaine is not new. In the 1960s, some people who used heroin reported that it reduced opioid dependence, according to a historical review published in 2026 in the Journal of Psychedelic Studies.

But cases of arrhythmia and deaths from cardiac arrest during detoxification therapies, combined with a thin base of clinical study, led many countries to restrict or ban the substance.

Where ibogaine is unregulated or legal, treatment clinics have multiplied over the past decade or so in places like Mexico, Canada and New Zealand, sometimes with little medical oversight.

‘There are still thousands of people using ibogaine without even basic information,’ Genis Ona, a study coordinator at Sant Joan de Deu Hospital’s Clinical Research Unit in Barcelona, told Mongabay, adding that a clinical setting is the best place to gather high-quality safety data.

Medical Safety Callout

Ibogaine is not an approved detox medication. It has been linked to dangerous heart rhythm changes and cardiac arrest, which is why any exposure belongs in a monitored medical setting rather than an unregulated clinic or an at-home attempt.

This is very different from evidence-based medication-assisted treatment (MAT) for opioid use disorder, where medications like buprenorphine, methadone, and naltrexone have established safety records and regulatory approval.

Why Medical Detox Matters

The ibogaine story captures a broader truth about detox: the goal is not just stopping a substance, but doing so safely.

Opioid withdrawal is rarely life-threatening on its own, but it is intensely uncomfortable and carries a high relapse and overdose risk without support. Alcohol and benzodiazepine withdrawal can be life-threatening and should never be attempted without medical supervision.

Finding Medical Detox

If you are considering detox, look for medically supervised programs where clinicians can monitor your heart, manage symptoms,and transition you into ongoing care.

Detox.com’s directory features verified detox centers that can help you have a safe withdrawal. Call 800-996-6135(Sponsored) to find medically supervised detox programs near you.